A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517284-23-00

Acronym

77242113PSA3002

Enrollment

401

Registered

2025-04-14

Start date

2025-04-23

Completion date

Unknown

Last updated

2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active Psoriatic Arthritis

Brief summary

The primary endpoint is the American College of Rheumatology (ACR) 20 response at Week 16

Interventions

DRUGJNJ-77242113

DRUGJNJ-77242113-AAC Placebo tablet

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the American College of Rheumatology (ACR) 20 response at Week 16	—

Countries

Bulgaria, Czechia, Denmark, Germany, Hungary, Italy, Poland, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026